PRTA News and Press, Prothena Corporation plc

2026-05-08 07:15:08 ET Citigroup analyst issues OUTPERFORM recommendation for PRTA on May 8, 2026 10:07AM ET. The previous analyst recommendation was Outperform. PRTA was trading at $10.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...

Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after the clo...

2026-04-27 17:30:25 ET More on Novo Nordisk A/S Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It? Novo Nordisk's Weight Loss Doesn't Mean To Load Up Novo Nordisk: Intense Competition Within The GLP-1 Duopoly Novo’s Wegovy expands reach in...

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participants with ATTR-CM; primary completion expected in 2...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates to its leadership team. Annie Kingston is being promoted to Chief Strategy Officer and Micha...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson’s ...

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk Prothena Corporation plc (NASDAQ...

2026-03-03 13:50:10 ET The last time I spoke about Prothena Corporation plc ( PRTA ), it was in a Seeking Alpha article entitled " Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place ." I went over two of its main clinical programs, which were ...

2026-02-27 16:24:45 ET More on Prothena Prothena Corporation plc 2025 Q4 - Results - Earnings Call Presentation Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript Prothena Corporation plc (PRTA) Presents at Evercore 8th Annual Healthcare Conference Tran...